import type { Metadata } from "next";
import ClinicalArticleLayout from "@/components/ClinicalArticleLayout";
import Link from "next/link";

export const metadata: Metadata = {
  title: { absolute: "Fasting Insulin Blood Test UK: Private Testing for Insulin Resistance | Veridian Clinic" },
  description:
    "A private fasting insulin blood test in the UK reveals early insulin resistance years before HbA1c rises. Not offered on NHS routine screening. Included in the Energy & Fatigue panel (£249) and Metabolic Baseline (£595). Results interpreted by a GP, with a personalised action plan.",
  alternates: {
    canonical: "https://veridianclinic.com/blood-tests/fasting-insulin",
  },
  openGraph: {
    title: "Fasting Insulin Blood Test UK: Private Testing for Insulin Resistance | Veridian Clinic",
    description:
      "Private fasting insulin testing in the UK. The NHS doesn't routinely offer it, yet it's one of the most actionable early markers for metabolic dysfunction, PCOS, cardiovascular risk, and fatigue.",
    url: "https://veridianclinic.com/blood-tests/fasting-insulin",
    type: "article",
  },
  keywords: [
    "fasting insulin test UK",
    "insulin resistance blood test UK",
    "fasting insulin private UK",
    "HOMA-IR test UK",
    "fasting insulin normal range UK",
    "hyperinsulinaemia blood test UK",
    "PCOS insulin resistance test UK",
    "metabolic health blood test UK",
    "private metabolic screening UK",
    "early diabetes risk test UK",
    "fasting insulin optimal range UK",
    "insulin resistance symptoms UK",
  ],
};

const paragraph = { fontSize: ".96rem", color: "var(--sl2)", lineHeight: 1.95 } as const;
const sectionHeading = { fontSize: "2rem", fontWeight: 500, color: "var(--sl)" } as const;
const callout = { padding: "18px 20px", background: "var(--iv)", borderLeft: "3px solid var(--go)" } as const;

const schema = {
  "@context": "https://schema.org",
  "@type": "Article",
  headline: "Fasting Insulin Blood Test UK: Private Testing for Insulin Resistance",
  description:
    "A private fasting insulin blood test reveals early insulin resistance years before HbA1c or fasting glucose become abnormal. Not offered on routine NHS screening, yet one of the most clinically actionable markers in preventive metabolic medicine.",
  author: { "@type": "Person", name: "Dr Oluwatosin Taiwo", url: "https://veridianclinic.com" },
  publisher: {
    "@type": "Organization",
    name: "Veridian Clinic",
    url: "https://veridianclinic.com",
    logo: { "@type": "ImageObject", url: "https://veridianclinic.com/og-image.jpg" },
  },
  datePublished: "2026-05-11",
  dateModified: "2026-05-11",
  mainEntityOfPage: { "@type": "WebPage", "@id": "https://veridianclinic.com/blood-tests/fasting-insulin" },
  image: "https://veridianclinic.com/og-image.jpg",
};

export default function FastingInsulinTestPage() {
  return (
    <>
      <script
        type="application/ld+json"
        dangerouslySetInnerHTML={{ __html: JSON.stringify(schema) }}
      />
      <ClinicalArticleLayout
        eyebrow="Private Blood Tests UK"
        title="Fasting insulin blood test UK: the early metabolic marker the NHS doesn&apos;t routinely test"
        intro="Fasting insulin is one of the most clinically useful markers in preventive metabolic medicine, and one of the most under-requested. A normal fasting glucose does not rule out early insulin resistance. Fasting insulin measures directly whether the system is already under compensatory strain, often years before standard NHS tests catch the problem."
        ctas={[
          { href: "/book?tier=fatigue-energy", label: "Book Energy & Fatigue Panel (fasting insulin included) £249 →" },
          { href: "/book?tier=baseline", label: "Book Metabolic Baseline £595", variant: "secondary" },
        ]}
      >
        <p style={paragraph}>
          The NHS does not include fasting insulin as part of routine metabolic or diabetes screening. Instead, standard panels rely on fasting glucose and HbA1c, both of which measure the outcome of insulin action (blood glucose control) rather than the insulin burden itself. This creates a significant gap: a person can have fasting glucose of 5.2 mmol/L and HbA1c of 37 mmol/mol, both within normal limits, while their pancreas is already secreting two or three times the insulin it should need to maintain that apparently healthy glucose level. Fasting insulin captures this compensatory hyperinsulinaemia directly.
        </p>

        <div style={callout}>
          <p style={{ fontSize: ".88rem", color: "var(--sl2)", lineHeight: 1.8 }}>
            <strong style={{ color: "var(--fo)" }}>Clinical bottom line:</strong> normal glucose does not mean normal metabolism. When insulin is elevated despite a normal glucose, it means the system is working harder than it should, and the window to restore insulin sensitivity is still wide open.
          </p>
        </div>

        <h2 className="cg" style={sectionHeading}>What does a fasting insulin blood test measure?</h2>
        <p style={paragraph}>
          A fasting insulin test measures the concentration of insulin in the blood after a minimum of eight to ten hours without caloric intake. It reflects the baseline insulin the body requires to maintain stable blood glucose during the rested, fasted state. An elevated result indicates that the pancreas is producing more insulin than would be expected for a given glucose level, the hallmark of insulin resistance, where tissues have become less responsive to insulin&apos;s signal and the body compensates by secreting more.
        </p>
        <p style={paragraph}>
          In the UK, laboratory reference ranges for fasting insulin vary by assay but are commonly quoted as 2-25 mIU/L or 3-17 mIU/L. These are population-derived ranges, not optimal values. A fasting insulin of 20 mIU/L may be flagged as &apos;normal&apos; while representing clinically significant hyperinsulinaemia with real-world consequences for cardiovascular risk, fat metabolism, energy, and hormonal function.
        </p>

        <h2 className="cg" style={sectionHeading}>Optimal fasting insulin ranges vs laboratory normal</h2>
        <p style={paragraph}>
          In preventive and longevity medicine, the clinically meaningful thresholds are significantly tighter than standard laboratory ranges:
        </p>
        <ul className="chk">
          <li><strong>Optimal:</strong> fasting insulin 2-6 mIU/L, associated with strong insulin sensitivity and low metabolic risk.</li>
          <li><strong>Borderline:</strong> 6-10 mIU/L; warrants dietary, exercise, and lifestyle review; trend should be tracked.</li>
          <li><strong>Elevated:</strong> 10-15 mIU/L, consistent with early-to-moderate insulin resistance; active intervention indicated.</li>
          <li><strong>Significantly elevated:</strong> above 15-20 mIU/L, established hyperinsulinaemia; associated with meaningful cardiometabolic risk and often visible in central adiposity, dyslipidaemia, and elevated blood pressure.</li>
        </ul>
        <p style={paragraph}>
          Context matters enormously. These thresholds are guides rather than diagnostic cut-offs. A fasting insulin of 11 mIU/L in a 44-year-old with a waist circumference of 102 cm, triglycerides of 2.1 mmol/L, and poor sleep carries a very different clinical message than the same number in a lean, active 28-year-old. At Veridian, every fasting insulin result is interpreted alongside the full metabolic panel, not in isolation.
        </p>

        <h2 className="cg" style={sectionHeading}>HOMA-IR: how fasting insulin and glucose are combined</h2>
        <p style={paragraph}>
          HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) combines fasting insulin and fasting glucose to produce a single estimate of insulin resistance. The formula is: <strong>HOMA-IR = (fasting insulin in mIU/L × fasting glucose in mmol/L) ÷ 22.5</strong>.
        </p>
        <p style={paragraph}>
          HOMA-IR is particularly useful for identifying patients where both values sit in the &apos;high normal&apos; zone of their respective ranges and whose combination reveals a degree of insulin resistance that neither would show alone. Working thresholds:
        </p>
        <ul className="chk">
          <li><strong>Below 1.0:</strong> insulin-sensitive, generally optimal.</li>
          <li><strong>1.0-1.9:</strong> borderline; worth monitoring and addressing lifestyle contributors.</li>
          <li><strong>2.0-2.9:</strong> meaningful insulin resistance; active metabolic management needed.</li>
          <li><strong>Above 3.0:</strong> significant insulin resistance, associated with metabolic syndrome, elevated cardiovascular risk, and MASLD.</li>
        </ul>
        <p style={paragraph}>
          HOMA-IR also tracks improvement well. A drop from 2.4 to 1.3 over twelve weeks of targeted intervention is measurable evidence that the metabolic pattern is moving towards remission, one of the most motivating data points a patient can receive.
        </p>

        <h2 className="cg" style={sectionHeading}>Why the NHS doesn&apos;t routinely test fasting insulin</h2>
        <p style={paragraph}>
          NHS diabetes screening is designed to detect established diabetes and impaired fasting glucose: conditions that are already symptomatic or that meet diagnostic criteria. Fasting insulin reflects a physiological state (compensatory hyperinsulinaemia) that precedes any diagnostic threshold and is not associated with a specific ICD-10 code that triggers intervention funding in the NHS framework.
        </p>
        <p style={paragraph}>
          This is not a clinical oversight so much as a structural consequence of a health system designed around disease treatment rather than early prevention. Fasting insulin testing adds genuine clinical value for identifying the patients most likely to develop metabolic disease over the following five to fifteen years, but that value is most visible when the goal is prevention rather than diagnosis.
        </p>
        <p style={paragraph}>
          It is also worth noting that fasting insulin assays have historically had less standardisation across laboratories than glucose measurements. However, within a single laboratory with a consistent assay, fasting insulin is a reliable and reproducible marker for tracking metabolic trajectory over time.
        </p>

        <h2 className="cg" style={sectionHeading}>Who should consider a private fasting insulin test in the UK?</h2>
        <ul className="chk">
          <li><strong>PCOS:</strong> insulin resistance is present in 65-80% of PCOS cases and directly drives the hormonal dysregulation, androgen excess, and anovulatory cycles. Most NHS PCOS workups do not include fasting insulin, leaving the primary driver unaddressed.</li>
          <li><strong>Central adiposity:</strong> anyone with a waist circumference above 94 cm (men) or 80 cm (women), regardless of BMI: visceral fat drives insulin resistance and is itself driven by chronically elevated insulin.</li>
          <li><strong>Elevated triglycerides:</strong> TG above 1.5 mmol/L on a routine lipid panel is often the earliest measurable signal of insulin resistance and atherogenic dyslipidaemia.</li>
          <li><strong>Unexplained fatigue, energy crashes, or carbohydrate cravings:</strong> the energy instability driven by postprandial glucose variability is a direct downstream consequence of hyperinsulinaemia in many patients.</li>
          <li><strong>Family history of type 2 diabetes or cardiovascular disease:</strong> genetic susceptibility to insulin resistance is meaningful; identifying it early maximises the intervention window.</li>
          <li><strong>Anyone who has been told their diabetes risk markers are &apos;fine&apos; but suspects something is off:</strong> fasting insulin is the test most likely to reveal the pattern that standard glucose-focused screening misses.</li>
        </ul>

        <h2 className="cg" style={sectionHeading}>How fasting insulin fits into Veridian&apos;s assessment panels</h2>
        <p style={paragraph}>
          Fasting insulin is included in Veridian&apos;s Energy &amp; Fatigue panel (£249), a panel designed for people experiencing unexplained fatigue or energy dysfunction, and in the Metabolic Baseline (£595), the most comprehensive assessment for overall metabolic health.
        </p>
        <p style={paragraph}>
          In the Metabolic Baseline, fasting insulin is interpreted alongside fasting glucose, HbA1c, lipid profile, ApoB, liver function and thyroid function, which allows HOMA-IR to be calculated and ApoB discordance to be identified. In the Energy &amp; Fatigue panel it is interpreted alongside thyroid function, ferritin, B12, vitamin D, uric acid and CRP, so the metabolic contribution to fatigue is weighed against the other drivers before recommendations are made.
        </p>
        <p style={paragraph}>
          Every result is accompanied by a GP-written report covering what each marker means for you, whether HOMA-IR is in the optimal or intervention range, and a prioritised action plan that identifies which interventions are most likely to move fasting insulin in the right direction based on your specific results.
        </p>

        <ul className="chk">
          <li>Fasting insulin included in the Energy &amp; Fatigue panel (£249) and Metabolic Baseline (£595).</li>
          <li>HOMA-IR calculated from fasting insulin and fasting glucose.</li>
          <li>Nationally accredited UK laboratory processing.</li>
          <li>GP-written results report with personalised action plan.</li>
        </ul>

        <p style={{ fontSize: ".9rem", color: "var(--sl3)", lineHeight: 1.8, borderTop: "1px solid rgba(0,0,0,.08)", paddingTop: 16 }}>
          Related reading:{" "}
          <Link href="/blog/fast-insulin" style={{ color: "var(--go)", textDecoration: "underline" }}>
            Fasting insulin: the missing early signal in metabolic disease
          </Link>
          {" · "}
          <Link href="/blog/reversing-metabolic-syndrome" style={{ color: "var(--go)", textDecoration: "underline" }}>
            Reversing metabolic syndrome: what the evidence supports
          </Link>
          {" · "}
          <Link href="/blog/apob-vs-ldl" style={{ color: "var(--go)", textDecoration: "underline" }}>
            ApoB vs LDL: cardiovascular particle count explained
          </Link>
        </p>

        {/* Related tests */}
        <div style={{ borderTop: "1px solid rgba(0,0,0,.08)", paddingTop: 24, marginTop: 8 }}>
          <p style={{ fontSize: ".72rem", fontWeight: 700, letterSpacing: ".2em", textTransform: "uppercase", color: "var(--go)", marginBottom: 16 }}>Related Tests</p>
          <div style={{ display: "grid", gap: 10 }}>
            {[
              { href: "/blood-tests/apob", label: "ApoB Blood Test", note: "From £595 (Metabolic Baseline)" },
              { href: "/blood-tests/fatigue-energy", label: "Energy & Fatigue Panel", note: "£249" },
              { href: "/blood-tests/lipoprotein-a", label: "Lipoprotein(a) Test", note: "From £795 (Longevity Panel)" },
              { href: "/blood-tests/biological-age", label: "Biological Age Test", note: "£795 (Longevity Panel)" },
              { href: "/blood-tests/metabolic-weight", label: "Metabolic Weight Resistance Panel", note: "£199" },
              { href: "/assessments", label: "View All Panels & Pricing", note: "Assessments" },
            ].map((t) => (
              <Link key={t.href} href={t.href} style={{ display: "flex", justifyContent: "space-between", alignItems: "center", padding: "10px 14px", background: "var(--iv)", border: "1px solid rgba(0,0,0,.07)", textDecoration: "none" }}>
                <span style={{ fontSize: ".88rem", color: "var(--sl)", fontWeight: 500 }}>{t.label}</span>
                <span style={{ fontSize: ".78rem", color: "var(--sl3)" }}>{t.note} →</span>
              </Link>
            ))}
          </div>
        </div>
      </ClinicalArticleLayout>
    </>
  );
}
